Does Wegovy Affect Liver Enzymes — and Should You Be Concerned?

What happens to liver enzymes when weight falls

The liver stores excess fat when more energy arrives than the body uses. In people with obesity, this often shows up as raised alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) on a blood panel. These elevations are not a coincidence, they are a direct signal of fat accumulation in liver tissue.

When semaglutide reduces appetite and food intake, the liver gradually clears its fat stores. Multiple studies in adults with obesity and metabolic liver disease have shown consistent reductions in ALT and AST alongside weight loss. The MHRA's July 2026 approval of Wegovy for a form of fatty liver disease called MASH (metabolic-associated steatohepatitis with moderate-to-advanced fibrosis) is the most direct regulatory signal yet that semaglutide's effects on liver health are clinically meaningful. You can read more about how semaglutide affects the liver in its own right.

The practical implication: if your enzymes are elevated because of excess weight and metabolic stress, losing 10–15% of body weight (which semaglutide achieves for many people) often brings those numbers down without any separate liver treatment. The NHS page on semaglutide covers the general side-effect and health profile in plain language, and is a good first reference for anyone with questions about the medicine's wider effects.

When enzyme rises on Wegovy are a reason to pay attention

Not every enzyme change on semaglutide is reassuring. A smaller subset of people on GLP-1 medicines see a transient rise in liver enzymes during the first few months of treatment. This is not fully explained, but proposed mechanisms include rapid mobilisation of liver fat, changes in bile flow, or gallbladder effects, gallstone formation is a recognised side effect when losing weight quickly on any intervention, and gallstones can irritate bile ducts and lift liver enzymes.

Separately, semaglutide slows gastric emptying, which affects how other medicines are absorbed. Anyone taking medications that require stable hepatic metabolism should discuss this with their prescriber.

If you notice yellowing of the skin or eyes, dark urine, or persistent upper-right abdominal discomfort, these are signs that warrant prompt medical attention, not a wait-and-see approach. The MHRA's Yellow Card reporting system at yellowcard.mhra.gov.uk exists partly so that unusual reactions (including unexpected liver findings) are systematically captured across the population using these medicines. Reporting is open to patients and healthcare professionals alike.

Those with a history of cholestatic liver disease or biliary obstruction are listed in the medicine's Summary of Product Characteristics as a group requiring careful assessment. The full contraindications and precautions are set out in the detail on whether Wegovy can affect your liver, including the gallbladder angle.

Pre-existing liver conditions and starting semaglutide

Having raised liver enzymes before starting Wegovy does not automatically disqualify you from treatment. In fact, the NICE appraisal of semaglutide for weight management, TA875, was developed with full knowledge that metabolic liver disease is common in the population this medicine serves. The question is the cause and severity of the elevation.

Mild-to-moderate elevation caused by fatty liver and obesity is, if anything, one of the conditions semaglutide may help over time. Elevation caused by active hepatitis, cirrhosis, or drug-induced liver injury is a different matter and needs specialist input before starting any weight-loss medicine.

A checking habit worth building: if you have existing blood results, look at the date and compare the enzyme figures to your GP's reference range before your consultation. A recent panel (ideally from the past three to six months) gives our prescribers something concrete to work with. Sharing that context upfront means the clinical review focuses on the right questions from the start. You can read about what high liver enzymes on Wegovy mean in practice if your results have already raised a flag.

Wegovy is a prescription-only medicine; a GPhC-registered Independent Prescriber at our pharmacy reviews every consultation personally before any treatment is issued. Pre-existing liver conditions are part of what that review covers, not a checkbox, but a genuinely clinical read of your history. If you are exploring your options, the consultation page is the place to start.

What remains uncertain, and who to involve

The evidence base for semaglutide's liver effects is growing fast (the July 2026 MASH licence came on the back of a substantial phase-3 trial) but long-term data beyond three years in liver-specific populations is still accumulating. If you want a focused overview of how Wegovy affects the liver, including what the current evidence does and does not cover, that page brings the key points together in one place. What we do not yet have is strong evidence on optimal monitoring frequency for people with pre-existing liver disease who start semaglutide outside a trial setting. Current practice follows general clinical judgement: baseline enzymes where relevant, a repeat at three to six months, and further testing if symptoms arise.

Who to involve depends on your starting point. If your enzymes are mildly raised and your GP attributes this to weight and metabolic syndrome, your prescriber and GP between them can manage the picture. If you have a formal liver diagnosis (MASH, non-alcoholic cirrhosis, viral hepatitis) a hepatologist's view before starting any weight-loss medicine is appropriate. Our prescribers flag this clearly where the consultation history warrants it.

For anyone weighing up the full semaglutide picture (how the medicine works, what results the trials showed, and what to expect from week one) finding a safe, regulated source of Wegovy starts with understanding what a legitimate clinical pathway actually looks like. Our clinical team publishes its approach openly, and you can explore all weight-loss treatment options before deciding.